114 related articles for article (PubMed ID: 37708846)
1. Fortifying immunity: PLSCR1 picks battle against SARS-CoV-2.
Li M
Cell Host Microbe; 2023 Sep; 31(9):1417-1419. PubMed ID: 37708846
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
3. PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection.
Xu D; Jiang W; Wu L; Gaudet RG; Park ES; Su M; Cheppali SK; Cheemarla NR; Kumar P; Uchil PD; Grover JR; Foxman EF; Brown CM; Stansfeld PJ; Bewersdorf J; Mothes W; Karatekin E; Wilen CB; MacMicking JD
Nature; 2023 Jul; 619(7971):819-827. PubMed ID: 37438530
[TBL] [Abstract][Full Text] [Related]
4. Clash of the titans: interferons and SARS-CoV-2.
Jouvenet N; Goujon C; Banerjee A
Trends Immunol; 2021 Dec; 42(12):1069-1072. PubMed ID: 34742657
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors.
Kumar A; Ishida R; Strilets T; Cole J; Lopez-Orozco J; Fayad N; Felix-Lopez A; Elaish M; Evseev D; Magor KE; Mahal LK; Nagata LP; Evans DH; Hobman TC
J Virol; 2021 Jun; 95(13):e0026621. PubMed ID: 34110264
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection.
Li M; Ayyanathan K; Dittmar M; Miller J; Tapescu I; Lee JS; McGrath ME; Xue Y; Vashee S; Schultz DC; Frieman MB; Cherry S
mBio; 2023 Aug; 14(4):e0119423. PubMed ID: 37377442
[TBL] [Abstract][Full Text] [Related]
7. Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection.
Mihaescu G; Chifiriuc MC; Filip R; Bleotu C; Ditu LM; Constantin M; Cristian RE; Grigore R; Bertesteanu SV; Bertesteanu G; Vrancianu CO
Front Immunol; 2023; 14():1273604. PubMed ID: 38288121
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of impairment of interferon production by SARS-CoV-2.
Hoang HD; Naeli P; Alain T; Jafarnejad SM
Biochem Soc Trans; 2023 Jun; 51(3):1047-1056. PubMed ID: 37199495
[TBL] [Abstract][Full Text] [Related]
9. Interferon antagonists encoded by SARS-CoV-2 at a glance.
Lee JH; Koepke L; Kirchhoff F; Sparrer KMJ
Med Microbiol Immunol; 2023 Apr; 212(2):125-131. PubMed ID: 35366686
[TBL] [Abstract][Full Text] [Related]
10. Innate immunity and interferon in SARS-CoV-2 infection outcome.
Savan R; Gale M
Immunity; 2023 Jul; 56(7):1443-1450. PubMed ID: 37437537
[TBL] [Abstract][Full Text] [Related]
11. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies.
Zhang S; Wang L; Cheng G
Mol Ther; 2022 May; 30(5):1869-1884. PubMed ID: 35176485
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of interferons in innate responses to mucosal viral infections.
Walker FC; Sridhar PR; Baldridge MT
Trends Immunol; 2021 Nov; 42(11):1009-1023. PubMed ID: 34629295
[TBL] [Abstract][Full Text] [Related]
14. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
15. Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4).
Kaur R; Tada T; Landau NR
mBio; 2023 Aug; 14(4):e0109023. PubMed ID: 37382452
[TBL] [Abstract][Full Text] [Related]
16. Nonproductive exposure of PBMCs to SARS-CoV-2 induces cell-intrinsic innate immune responses.
Kazmierski J; Friedmann K; Postmus D; Emanuel J; Fischer C; Jansen J; Richter A; Bosquillon de Jarcy L; Schüler C; Sohn M; Sauer S; Drosten C; Saliba AE; Sander LE; Müller MA; Niemeyer D; Goffinet C
Mol Syst Biol; 2022 Aug; 18(8):e10961. PubMed ID: 35975552
[TBL] [Abstract][Full Text] [Related]
17. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2.
Beyer DK; Forero A
J Mol Biol; 2022 Mar; 434(6):167265. PubMed ID: 34562466
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
[TBL] [Abstract][Full Text] [Related]
20. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics.
Cheemarla NR; Watkins TA; Mihaylova VT; Wang B; Zhao D; Wang G; Landry ML; Foxman EF
J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34128960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
